Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KTZ-S 2% vs placebo for seborrhoeic dermatitis of the scalp
jRCT2031250479Completed
- Sponsor
- SEREN Pharmaceuticals
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in seborrheic dermatitis (SD) comparing KTZ-S 2% once daily with Placebo once daily (2 arms). Primary endpoint: Primary: Change in total scalp symptom score (TSS). Started Dec 2025; status: completed.
02
Drugs
KTZ-S
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on jRCT2031250479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250479.